Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

Company Overview - Oragenics, Inc. is a biotechnology company focused on developing intranasal therapeutics for neurological disorders [3] - The company's lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion [3] Upcoming Events - Oragenics will present at the 2025 BIO International Convention from June 16–19, 2025, in Boston, Massachusetts [1] - The company will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium from June 15–18, 2025, in Philadelphia, Pennsylvania [1][2] Product Focus - ONP-002 is an intranasal neurosteroid aimed at treating concussion, utilizing a delivery technology designed for fast, targeted, and non-invasive therapy to the brain [2][3]